Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
A Swiss research program tested for and treated hep C in a large cohort of HIV-positive men who have sex with men over time.
This is according to a recent study of a group of European men who have sex with men who were likely infected sexually.
The ongoing cohort of men who have sex with men living with HIV had a hep C prevalence rate of about 5 percent.
Merck’s hepatitis C treatment cured almost all those with stages 3 through 5 of chronic kidney disease in a VA database.
The U.S. Food and Drug Administration (FDA) has approved Merck’s once-daily fixed-dose combination tablet Zepatier (grazoprevir/elbasvir)
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.